Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ALPL | P05186 | 2/20 | 0.32 |
| ▸ | ALPI | P09923 | 2/20 | 0.32 |
| ▸ | ALPG | P10696 | 2/20 | 0.32 |
| ▸ | IDH1 | O75874 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | PRKCA | P17252 | 3/20 | 0.31 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.31 |
| ▸ | HTR2B | P41595 | 2/20 | 0.31 |
| ▸ | FLT3 | P36888 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1241651 | 1.00 | DGAT2 (0.35) | DGAT2HCRTR1L3MBTL1ALPLALPI | |
| SCHEMBL1241145 | 0.89 | SGMS2 (0.36) | HCRTR1IDH1SMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL1240374 | 0.89 | SGMS2 (0.36) | HCRTR1IDH1SMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL1241142 | 0.89 | SGMS2 (0.36) | HCRTR1IDH1SMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL1240372 | 0.89 | SGMS2 (0.36) | HCRTR1IDH1SMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL1241089 | 0.88 | DGAT2 (0.39) | DGAT2HCRTR1L3MBTL1ALPLALPI | |
| SCHEMBL1241092 | 0.88 | DGAT2 (0.39) | DGAT2HCRTR1L3MBTL1ALPLALPI | |
| SCHEMBL1241085 | 0.88 | DGAT2 (0.39) | DGAT2HCRTR1L3MBTL1ALPLALPI | |
| SCHEMBL1238446 | 0.87 | HCRTR1 (0.33) | HCRTR1IDH1PRKCAPRKCQHTR2B | |
| SCHEMBL1238442 | 0.87 | HCRTR1 (0.33) | HCRTR1IDH1PRKCAPRKCQHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809380-B2 | Picolinamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2014-08-19 | — | — | US | claimed |
| US-20120142691-A1 | PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. | 2012-06-07 | — | — | US | claimed |
| WO-2011016234-A1 | PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2011-02-10 | — | — | WO | claimed |
| US-8969383-B2 | Picolinamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-03-03 | — | — | US | disclosed |
| US-8969383-B2 | Picolinamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-03-03 | — | — | US | disclosed |
| US-20140296237-A1 | PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC (JP) | 2014-10-02 | — | — | US | disclosed |
| US-20140296237-A1 | PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC (JP) | 2014-10-02 | — | — | US | disclosed |
| US-8809380-B2 | Picolinamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2014-08-19 | — | — | US | disclosed |
| US-8809380-B2 | Picolinamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2014-08-19 | — | — | US | disclosed |
| US-20120142691-A1 | PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. | 2012-06-07 | — | — | US | disclosed |
| US-20120142691-A1 | PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. | 2012-06-07 | — | — | US | disclosed |
| WO-2011016234-A1 | PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2011-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142691-A1 | PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS | CACNA1G, SCN3A, SCN5A | DGAT2 3062/4885HCRTR1 471/4885L3MBTL1 3282/4885 |
| US-20140296237-A1 | PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS | CACNA1G, SCN3A, SCN5A | DGAT2 3062/4885HCRTR1 471/4885L3MBTL1 3282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.